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Adjuvant external beam radiotherapy in the treatment of 
endometrial cancer (MRC ASTEC and NCIC CTG EN.5 
randomised trials): pooled trial results, systematic review, 
and meta-analysis
The ASTEC/EN.5 writing committee on behalf of the ASTEC/EN.5 Study Group*
Summary
Background Early endometrial cancer with low-risk pathological features can be successfully treated by surgery alone. 
External beam radiotherapy added to surgery has been investigated in several small trials, which have mainly included 
women at intermediate risk of recurrence. In these trials, postoperative radiotherapy has been shown to reduce the risk 
of isolated local recurrence but there is no evidence that it improves recurrence-free or overall survival. We report the 
ﬁ ndings from the ASTEC and EN.5 trials, which investigated adjuvant external beam radiotherapy in women with 
early-stage disease and pathological features suggestive of intermediate or high risk of recurrence and death from 
endometrial cancer.
Methods Between July, 1996, and March, 2005, 905 (789 ASTEC, 116 EN.5) women with intermediate-risk or high-risk 
early-stage disease from 112 centres in seven countries (UK, Canada, Poland, Norway, New Zealand, Australia, USA) 
were randomly assigned after surgery to observation (453) or to external beam radiotherapy (452). A target dose of 
40–46 Gy in 20–25 daily fractions to the pelvis, treating ﬁ ve times a week, was speciﬁ ed. Primary outcome measure 
was overall survival, and all analyses were by intention to treat. These trials were registered ISRCTN 16571884 (ASTEC) 
and NCT 00002807 (EN.5).
Findings After a median follow-up of 58 months, 135 women (68 observation, 67 external beam radiotherapy) had died. 
There was no evidence that overall survival with external beam radiotherapy was better than observation, hazard 
ratio 1·05 (95% CI 0·75–1·48; p=0·77). 5-year overall survival was 84% in both groups. Combining data from ASTEC 
and EN.5 in a meta-analysis of trials conﬁ rmed that there was no beneﬁ t in terms of overall survival (hazard ratio 1·04; 
95% CI 0·84–1·29) and can reliably exclude an absolute beneﬁ t of external beam radiotherapy at 5 years of more than 
3%. With brachytherapy used in 53% of women in ASTEC/EN.5, the local recurrence rate in the observation group at 
5 years was 6·1%.
Interpretation Adjuvant external beam radiotherapy cannot be recommended as part of routine treatment for women 
with intermediate-risk or high-risk early-stage endometrial cancer with the aim of improving survival. The absolute 
beneﬁ t of external beam radiotherapy in preventing isolated local recurrence is small and is not without toxicity.
Funding Medical Research Council, National Cancer Research Network, National Cancer Institute of Canada, with 
funds from the Canadian Cancer Society.
Introduction
After surgery for endometrial cancer, external beam 
radiotherapy has been oﬀ ered to women with early disease 
(International Federation of Gynecology and Obstetrics 
[FIGO] stage I and IIA) whose pathological features 
indicate an increased likelihood of nodal metastases at 
diagnosis and who might therefore beneﬁ t from adjuvant 
treatment. These pathological features have included 
histological type, grade, and depth of myometrial invasion. 
There are national and international variations in the 
deﬁ nitions of intermediate and high risk, the types of 
women oﬀ ered adjuvant radiotherapy as part of routine 
clinical practice, and the range of stage I and IIA women 
entered into clinical trials. In addition to external beam 
radiotherapy, local vaginal radiotherapy (brachytherapy) is 
also used to prevent cancer recurrence.
EN.5 and ASTEC were set up as individual trials to 
investigate the beneﬁ t or otherwise of postoperative 
adjuvant pelvic radiotherapy in women with early 
endometrial cancer and pathological features suggestive 
of intermediate or high risk of recurrence and death. The 
EN.5 trial of the National Cancer Institute of Canada 
(NCIC) Clinical Trials Group started in 1996, but could not 
recruit suﬃ  cient patient numbers to complete the study 
as it was originally envisaged. In 1998, the UK Medical 
Research Council (MRC) launched ASTEC, and invited 
the NCIC Clinical Trials Group to plan a prospective 
combination of the EN.5 data with those of ASTEC. 
ASTEC/EN.5 therefore consists of two trials with separate 
randomisations combined to make one intergroup trial.
A recent systematic review and meta-analysis1 identiﬁ ed 
four completed randomised trials2–5 which assessed the 
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beneﬁ t of adjuvant external beam radiotherapy in women 
with early endometrial cancer. Data for 1770 women 
(including 258 deaths) in these trials showed that adjuvant 
radiotherapy reduces the risk of pelvic recurrence, but 
there was no evidence that it improves overall survival.1 
The ASTEC and EN.5 trials with 905 women (and 
135 deaths) provide additional data, particularly for high-
risk women within stage I disease, who were under-
represented in the earlier trials, and could allow smaller, 
clinically important diﬀ erences to be reliably detected.
Methods
Participants
Eligible women had histologically conﬁ rmed endometrial 
cancer, macroscopically conﬁ ned to the uterine corpus 
(FIGO stage I) or endocervical glands (IIA), with 
pathological features suggestive of an intermediate or 
high risk of recurrence including: FIGO stage IA and IB 
grade 3; IC all grades; papillary serous; or clear cell 
histology all stages and grades (table 1).6 Lymphadenectomy 
as part of surgical staging was not a requirement for 
randomisation. Positive para-aortic nodes were viewed as 
indicative of unrecognised macroscopic disease and were 
an exclusion to randomisation. Pelvic lymph nodes could 
be negative or not examined; women with positive pelvic 
lymph nodes were eligible for ASTEC but not for EN.5. 
Peritoneal cytology could be negative, positive, or not 
done. Women had to be ﬁ t to receive external beam 
radiotherapy and all women gave written, informed 
consent. Women in the ASTEC surgical trial gave consent 
for both surgical and radiotherapy randomisations before 
surgery. Ethics approval for the trial was obtained from 
the North West Multi Centre Regional Ethics Committee 
in the UK and each participating institution in Canada.
Procedures
Eligible women were randomly allocated after surgery to 
either the observation group with no external beam 
radiotherapy or systemic treatment until recurrence, or to 
the external beam radiotherapy group. Radiotherapy was 
started as soon as possible after wound healing, 6–8 weeks 
after surgery. In EN.5, a speciﬁ ed date on which 
radiotherapy would occur (if allocated) was available at 
randomisation and that date was no later than 12 weeks 
after surgery. A target dose of 40–46 Gy (45 Gy in EN.5) in 
20–25 daily fractions (25 fractions in EN.5) to the pelvis, 
treating ﬁ ve times a week was speciﬁ ed. Brachytherapy 
was allowed if the centre’s policy was to oﬀ er it to all 
stage I or IIA women irrespective of radiotherapy 
allocation. In ASTEC, two fractions of 4 Gy at 0·5 cm over 
3–7 days at high dose rate or 15 Gy at low dose rate (50 cGy 
per h) was recommended to the upper third of the vagina. 
When using the LDR Selectron (Nucletron, Veenendaal, 
Netherlands) at around 170 cGy per h, a dose of 13·5 Gy at 
0·5 cm depth was suggested. In EN.5, brachytherapy was 
given in accordance with local practice.
Randomisation was done via telephone to the MRC 
Clinical Trials Unit (ASTEC centres) or to the NCIC 
Clinical Trials Group (EN.5 centres). Computer 
randomisation in both trials used a method of 
minimisation. In ASTEC, minimisation factors were 
centre, WHO performance status (0–1 vs 2–4), nodes 
involved (yes vs no), depth of invasion (inner half vs outer 
half), positive peritoneal cytology (yes vs no), and tumour 
grade (G1/G2 vs G3). In EN.5, minimisation factors were 
centre, tumour grade (G1 vs G2 vs G3), surgical staging 
deﬁ ned as at least one pelvic lymph node identiﬁ ed 
(yes vs no), and sexual health assessment (yes vs no). Each 
centre indicated its brachytherapy policy.
Randomisation was based on local pathology. In 
ASTEC, the minimum dataset of the Royal College of 
Pathologists was used as the standard for pathology 
reporting.7 Surgery and local pathology details were 
reviewed centrally at the MRC Clinical Trials Unit after 
randomisation. After randomisation in EN.5, central 
pathology review, with representative blocks from each 
patient, was done by two reference pathologists. For 
consistency, the primary analysis of ASTEC/EN.5 was 
based on the local pathology report.
The classiﬁ cation of women into intermediate and high 
risk was on the basis of risk of distant recurrence, 
previously deﬁ ned in the GOG99 and PORTEC1 studies.4,5 
High risk included all papillary serous and clear cell 
subtypes, all other subtypes in IC (grade 3), and IIA 
(grade 3) and all women in stage IIB. Intermediate risk 
included subtypes other than papillary serous and clear 
G1 G2 G3 Papillary 
serous/clear 
cell  
IA 1 (<1%) 1 (<1%) 8 (1%)* 15 (2%)†
IB 1 (<1%) 5 (1%) 99 (11%)* 48 (5%)†
IC 213 (24%)* 337 (37%)* 100 (11%)† 27 (3%)†
IIA 9 (1%)* 19 (2%)* 6 (1%)† 3 (<1%)†
IIB‡ 2 (<1%) 0 0 1 (<1%)
Data are number (%). Left column is FIGO stage. *Intermediate subgroup. All 
others would be deemed low risk. †High-risk subgroup. ‡IIB patients were not 
eligible but those randomised were included in the high-risk subgroup. 
Table 1: ASTEC/EN.5 FIGO stage and tumour grade entry criteria, 
intermediate-risk or high-risk classiﬁ cation, and patient distribution
905 randomised
453 observation
10 (2%) received external 
      beam radiotherapy
3 unknown
453 assessed for primary
outcome
68 deaths
452 assessed for primary
outcome
67 deaths
452 external beam radiotherapy
         416 (92%) received 
          external beam radiotherapy
   2 unknown
Figure 1: Trial proﬁ le
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cell histology within stage IA and IB (grade 3), and 
stage IC and IIA (grade 1 and 2; table 1).
In ASTEC, women were assessed before randomisation, 
after all postoperative treatment, including brachytherapy 
and external beam radiotherapy (if given), had been 
completed (around 3 months after pathology registration 
and 4 months after surgery), then roughly 6 months after 
pathology registration. In EN.5, women were assessed 
2 months after start of radiotherapy or 4 months after 
surgery. Follow-up in both trials continued every 3 months 
for the ﬁ rst year, every 6 months in years 2 and 3, and 
every year thereafter. Follow-up data included details of 
endometrial cancer recurrence and treatment, vital status, 
and short-term and long-term toxicities. Acute toxicity 
was assessed after completion of radiotherapy in those 
who received it, and roughly 4 months after completion of 
surgery in those who did not.
Statistical analysis
The primary outcome measure was overall survival. 
When the plan for the joint analysis of ASTEC and EN.5 
was developed, an overall sample size of 900 women was 
chosen to observe 130 events (deaths), to detect a 
10% improvement in 5-year overall survival from 75% in 
the observation group versus 85% in the external beam 
radiotherapy group (hazard ratio 0·56), with a 
5% signiﬁ cance level and 90% power. Combined with 
previous studies GOG993 and PORTEC1,4 this deﬁ nition 
would allow detection of a 6–7% absolute diﬀ erence in 
overall survival with 90% power. Also, combining ASTEC/
EN.5 participants with those from other major studies 
(speciﬁ cally GOG99 and PORTEC1) would allow reliable 
exclusion of an absolute diﬀ erence in 5-year overall 
survival of more than 5%, if there was no diﬀ erence 
detected, by determining the width of the 95% CI around 
a hazard ratio of 1·0.
Secondary outcome measures were disease-speciﬁ c 
survival, disease-speciﬁ c recurrence-free survival, isolated 
loco-regional recurrence, and treatment toxicity. Overall 
survival was deﬁ ned as the time from randomisation to 
death from any cause; women known to be still alive at 
the time of analysis were censored at the time of their 
last follow-up. Disease-speciﬁ c survival was deﬁ ned as 
time from randomisation to death from endometrial 
cancer or death due to treatment; deaths from other 
causes without disease recurrence were treated as a 
competing risk. Disease-speciﬁ c recurrence-free survival 
was deﬁ ned as time from randomisation to ﬁ rst 
appearance of endometrial cancer or death from 
endometrial cancer or due to treatment. Time to 
loco-regional recurrence was deﬁ ned as time from 
randomisation to vaginal or pelvic recurrence alone, and 
did not include women who had simultaneous local and 
distal recurrence or distal recurrence alone. In ASTEC, 
assessment of cause of death was made by the chief 
investigator blinded to treatment group, and was 
classiﬁ ed as treatment-related, disease-related, treatment 
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Figure 2: Kaplan-Meier plots for outcome measure 
EBRT=external beam radiotherapy.
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and disease-related, or other (non-endometrial cancer, 
non-treatment-related). Competing risk methods were 
used in the comparisons for disease-speciﬁ c survival and 
disease-speciﬁ c recurrence-free survival.8 The log-rank 
analysis was obtained indirectly by subtracting the 
log-rank statistic for non-endometrial cancer deaths from 
the log-rank statistic for all deaths (the two observed 
values were subtracted from each other; the two expected 
values were subtracted from each other; and the 
two variances were subtracted from each other).
The standard log-rank test was applied for all other 
time-to-event outcome measures. All comparisons are 
expressed relative to women in the observation group; a 
hazard ratio less than 1·0 indicates a decreased risk of 
the event for women in the external beam radiotherapy 
group. The absolute diﬀ erence between the treatment 
groups with time was modelled using the “stpm” 
command in Stata for the ﬂ exible parametric models of 
Royston and Parmar.9
Adjusted analyses using the Cox model were done to 
assess robustness of results. Covariates included the 
patient characteristics (age, WHO performance status, 
and whether lymphadenectomy was done) and pathology 
details (summarised as risk group) at baseline. Predeﬁ ned 
subgroups included women grouped by risk of recurrence 
and whether systematic lymphadenectomy was under-
taken as part of initial surgery. Other eﬀ ects of external 
beam radiotherapy on primary and secondary outcome Observation 
(N=453)
External beam 
radiotherapy 
(N=452)
Age (years)
Median (range) 66 (31–88) 65 (36–88)
WHO/Eastern Cooperative Oncology Group performance status
0 290 (64%) 304 (67%)
1 151 (33%) 136 (30%)
2 10 (2%) 11 (2%)
3 2 (<1%) 1 (<1%)
Surgery received
TAH/BSO 326 (72%) 313 (69%)
TAH/BSO/lymphadenectomy 127 (28%) 139 (31%)
Histology 
Endometrioid 372 (83%) 371 (83%)
Adenocarcinoma not otherwise 
speciﬁ ed
14 (3%) 18 (4%)
Clear cell 15 (3%) 7 (2%)
Papillary serous 23 (5%) 14 (3%)
Squamous 4 (1%) 6 (1%)
Mucinous 1 (<1%) 0
Mixed epithelial high grade 14 (3%) 21 (5%)
Mixed epithelial low grade 2 (<1%) 2 (<1%)
Other epithelial, other mixed or no 
details
4 (1%) 5 (1%)
Mixed epithelial stromal (ineligible) 0 2 (<1%)
Sarcoma (ineligible) 1 (<1%) 1 (<1%)
Unknown 3 5 
Diﬀ erentiation or grade
Well (G1) 107 (24%) 120 (27%)
Moderate (G2) 185 (41%) 180 (40%)
Poor (G3) 107 (24%) 107 (24%)
Clear cell/serous papillary/mixed 
epithelial high grade
52 (12%) 42 (9%)
Not applicable (sarcoma and mixed 
epithelial stromal)
2 (<1%) 3 (1%)
Lymphovascular permeation
Yes 102 (26%) 99 (25%)
No 293 (74%) 302 (75%)
Not mentioned in the pathology 
report
52 42
Unknown 6 9
(Continues in next column)
Observation 
(N=453)
External beam 
radiotherapy 
(N=452)
(Continued from previous column)
Positive peritoneal status
Yes 20 (5%) 15 (3%)
No 407 (95%) 415 (97%)
Not done 24 22
Unknown 2 0
Nodes present in pathology specimen
No 289 (68%) 265 (63%)
Yes 137 (32%) 159 (38%)
Unknown 27 28
Number of nodes removed
1–5 51 48
6–10 36 36
11–15 24 22
>15 21 48
Unknown 5 5
Median (range) number of nodes 
removed
8 (1–39) 10 (1–40)
Nodal involvement (if nodes removed)
No 132 (96%) 153 (96%)
Yes 5 (4%) 6 (4%)
FIGO stage
IA (endometrium only) 11 (2%) 15 (3%)
IB (<inner half myometrium) 79 (18%) 76 (17%)
IC (outer half myometrium) 336 (75%) 343 (76%)
IIA (endocervical gland invasion) 21 (5%) 16 (4%)
IIB (cervical stromal invasion) 3 (1%) 0
III/IV (spread beyond uterus or cervix) 0 1 (<1%)
Unknown 3 1 
Risk group
Intermediate risk 335 (75%) 358 (80%)
High risk 113 (25%) 89 (20%)
Unknown 5 5
TAH/BSO=total abdominal hysterectomy with bilateral salpingo-oopherectomy.
Table 2: Pretreatment characteristics, surgery received, and local 
pathology details reported at randomisation
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measures were assessed in an exploratory manner in 
subgroups. To test for diﬀ erences in the relative size of 
eﬀ ect in diﬀ erent subgroups, a χ2 test for interaction, or, 
when appropriate, a χ2 test for trend was used. All 
analyses were done on an intention-to-treat basis. All 
analyses on time-to-event outcome measure were 
stratiﬁ ed by the component of ASTEC versus EN.5. All 
p values are two-sided.
Established search strategies10 used in a previous 
meta-analysis1 were updated to identify other randomised 
trials of external beam radiotherapy in endometrial 
cancer, and the Cochrane database was searched for 
systematic reviews. Summary statistics abstracted from 
the identiﬁ ed studies were used in the analysis.
Role of the funding source
The MRC, as funder of ASTEC, reviewed and approved 
its design. The NCIC Clinical Trials Group reviewed the 
design of EN.5. The execution, and approval for com-
bination of the trials, was overseen by an independent 
data monitoring committee and independent trial 
steering committee. The sponsor of the study had no role 
in data collection, data analysis, data interpretation, or 
writing of the report. The writing committee had full 
access to all the data in the study, and the trial 
management group had ﬁ nal responsibility for the 
decision to submit for publication.
Results 
Between July, 1996, and March, 2005, 905 (789 ASTEC, 
116 EN.5) women from 112 centres in seven countries 
(UK, Canada, Poland, Norway, New Zealand, Australia, 
USA) were randomised: 453 to observation and 452 to 
external beam radiotherapy (ﬁ gure 1). Patient charac-
teristics at randomisation including details of sur gery and 
local pathology are shown in table 2. The predominant 
histological subtype was endo metrioid (83%). The 
baseline data were generally balanced between the two 
groups, except for a small imbalance in the proportion of 
high-risk women, with 25% of those in the observation 
group classiﬁ ed as high risk compared with 20% in the 
external beam radiotherapy group.
Observation 
(N=453)
External beam 
radiotherapy (N=452)
Acute toxicity
Any acute toxicity experienced
No 329 (73%) 191 (43%)
Yes 121 (27%) 258 (57%)
Unknown 3 3
Worst score of acute toxicity
Mild 77 (17%) 143 (32%)
Moderate 38 (8%) 100 (22%)
Severe or life threatening 3 (<1%) 14 (3%)
Unknown 3 1
Late toxicity
Any late toxicity experienced
No 251 (55%) 178 (39%)
Yes 202 (45%) 274 (61%)
Worst score of late toxicity
Mild 110 (24%) 135 (30%)
Moderate 71 (16%) 99 (22%)
Severe 15 (3%) 30 (7%)
Life threatening 0 4 (1%)
Unknown 6 6
Table 4: Toxicity
Observation 
(N=453)
External beam 
radiotherapy (N=452)
External beam radiotherapy only 3 (1%) 184 (41%)
External beam radiotherapy plus 
brachytherapy
7 (2%) 232 (52%)
Brachytherapy 228 (51%) 10 (2%)
None 212 (47%) 24 (5%)
Unknown 3 2
Table 3: Radiotherapy received
Observation 
(N=453)
External beam 
radiotherapy 
(N=452)
Total 
(N=905)
Overall survival
Alive 385 (85%) 385 (85%) 770 (85%)
Dead 68 (15%) 67 (15%) 135 (15%)
Cause of death
Disease related 39 41 80
Treatment related 0 1 1
Disease and treatment 1 1 2
Other 28* 22 50
Unknown 0 2 2
Recurrence-free survival
No recurrence or death 360 (79%) 368 (81%) 728 (80%)
Recurrence only 25 (5%) 17 (4%) 42 (5%)
Death only 27 (6%) 30 (7%) 57 (6%)
Recurrence and death 41 (9%) 37 (8%) 78 (9%)
Disease recurrence
No 387(85%) 398 (88%) 785 (87%)
Yes 66 (15%) 54 (12%) 120 (13%)
Site of ﬁ rst recurrence
Isolated vaginal or pelvic intial recurrence
Local/vaginal 17 7 24
Pelvic 12 5 17
Local vaginal plus pelvic 0 1 1
Distant with or without local recurrence
Local/vaginal and distant 3 1 4
Pelvic and distant 3 6 9
Distant 31 34 65
*Two patients with disease recurrence before death are included as events in 
disease-speciﬁ c and disease-speciﬁ c recurrence-free survival analyses.
Table 5: Summary of events
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Details of radiotherapy received are summarised in 
table 3. 92% of women randomised to external beam 
radiotherapy received it with or without brachytherapy. 
Median dose was 45 Gy in 25 fractions over 34 days, giving 
82% compliance with the planned dose of 40–46 Gy in 
20–25 fractions. Compliance with stated brachytherapy 
policy was 80%. Similar proportions of women in both 
groups received brachytherapy, with 235 (52%) in the 
observation group and 242 (54%) in the external beam 
radiotherapy group. Pretreatment characteristics of women 
who did and did not receive brachytherapy are shown in 
the webtable.
Adjuvant treatment for endometrial cancer before 
disease recurrence was given to a small proportion of 
women. In ASTEC, 40 (5%, 19 external beam radiotherapy, 
21 observation) women received hormone therapy and 
seven (1%, ﬁ ve external beam radiotherapy and two 
observation) received other treatment.
Reported toxicity is summarised in table 4. Acute 
toxicity after completion of all surgery and radiotherapy 
was greater in the external beam radiotherapy group than 
with observation (any toxicity: 121 women [27%] 
observation vs 258 women [57%] external beam 
radiotherapy; severe or life-threatening toxicity: three 
[<1%] observation vs 14 [3%] external beam radio therapy). 
Late toxicity, predominantly gastrointestinal or urogenital, 
was also more commonly reported after external beam 
radiotherapy (any late toxicity 202 women [45%] 
observation vs 274 [61%] external beam radiotherapy; 
severe toxicity 15 [3%] observation vs 30 [7%] external 
beam radiotherapy). Four women (1%), all of whom 
received external beam radiotherapy, were reported with 
life-threatening toxicity.
A summary of events is shown in table 5 and a summary 
of the primary comparisons with 5 year rates in table 6. 
Kaplan-Meier plots for the two treatment groups are shown 
in ﬁ gure 2. At the time of analysis, with a median follow up 
of 58 months, 135 (15%; 68 observation, 67 external beam 
radiotherapy) women had died. Overall survival curves 
showed no evidence of a diﬀ erence between the two groups 
with a hazard ratio of 1·05 (95% CI 0·75–1·48; p=0·77, 
ﬁ gure 2A). The 5-year overall survival was 84%.
A proportion of women did not die from endometrial 
cancer and had no disease recurrence before death. 
48 (36%) deaths (26 observation, 22 external beam 
radiotherapy) were classiﬁ ed as non-disease and 
non-treatment-related, whereas 87 (64%; 42 observation, 
45 external beam radiotherapy) women died from disease 
or treatment (including two women in the observation 
group with disease recurrence before death, table 5). An 
analysis which treated the non-disease, non-treatment-
related deaths as a competing risk showed a hazard ratio 
of 1·13 (95% CI 0·74–1·72; p=0·57, ﬁ gure 2B), although 
inevitably the conﬁ dence intervals are wider with fewer 
events in this analysis. The 5-year disease speciﬁ c survival 
for all women was 90% in the observation and 89% in the 
external beam radiotherapy group.
At the time of analysis, 129 women (67 observation, 
62 external beam radiotherapy) had disease recurrence or 
had died from endometrial cancer. Kaplan-Meier plots for 
disease-speciﬁ c recurrence-free survival are shown in 
ﬁ gure 2C. Competing risk analysis gave a hazard ratio 
of 0·93 (95% CI 0·66–1·31, p=0·68). The 5-year disease-
speciﬁ c recurrence-free survival was 84·7% in the 
observation group and 85·3% in the external beam radio-
therapy group, with no evidence of diﬀ erence on disease 
speciﬁ c recurrence-free survival between the two groups.
Total 
events
Unadjusted 5-year rate Absolute diﬀ erence in 
5-year rate  (95% CI)
Adjusted
Hazard ratio (95% CI) p value Observation EBRT Hazard ratio (95% CI) p value
Overall survival 135 1·05 (0·75 to 1·48) 0·77 83·9% 83·5% 0·4%(-5·0% to 5·7%) 1·19 (0·85–1·68) 0·31
Disease-speciﬁ c 
survival 
87 1·13 (0·74 to 1·72) 0·57 89·9% 88·5% 1·4%(-3·2% to 5·9%) 1·26 (0·83 to 1·94) 0·28
Disease-speciﬁ c 
recurrence-free 
survival
129 0·93 (0·66 to 1·31) 0·68 84·7% 85·3% 0·6%(-4·4% to 5·7%) 0·99 (0·70 to 1·40) 0·95
*Adjusted for age (continuous variable), WHO (0,1,2,3), risk group (intermediate vs high), and lymphadenectomy (yes, no). EBRT=external beam radiotherapy.
Table 6: Summary of comparisons for time to event outcome measures
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Figure 3: Isolated vaginal or pelvic initial recurrence 
EBRT=external beam radiotherapy.
See Online for webtable
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Site of recurrence is shown in table 5. The cumulative 
incidence of isolated vaginal or pelvic initial recurrence 
curves are shown in ﬁ gure 3. The hazard ratio for isolated 
vaginal or pelvic recurrence-free survival was 0·46 (95% CI 
0·24–0·89, p=0·02) with a 5-year cumulative incidence 
rate of 6·1% in the observation group and 3·2% in the 
external beam radiotherapy group, an absolute diﬀ erence 
of 2·9% (95% CI <0·1%–5·9%). Only 35% (42 of 120) of 
the total recurrences were isolated local recurrence, and 
although external beam radiotherapy seems to improve 
local control, this analysis excluded most women (78; 
37 observation, 41 external beam radiotherapy) who had 
local and distant recurrence or distant recurrence alone.
We also did analyses of overall survival, disease-speciﬁ c 
survival, and disease-speciﬁ c recurrence-free survival, 
adjusting for baseline characteristics using the Cox model 
(table 6). The results were similar to the unadjusted 
analysis. There was no evidence of a diﬀ erence in results 
according to randomising group (MRC Clinical Trials 
Unit vs NCIC). For the analyses of risk group interactions, 
exploratory analyses on overall survival and disease-
speciﬁ c survival are shown in ﬁ gure 4. Disease-speciﬁ c 
recurrence-free survival (chosen as the most sensitive 
because of number of events, and least confounded by 
deaths from causes other than endometrial cancer) was 
used to explore outcomes in women deﬁ ned as high and 
intermediate risk. The eﬀ ect of risk group on this outcome 
measure is shown in the webﬁ gure. The hazard ratio 
of 2·71 (95% CI 1·88–3·90; p<0·0001) shows that women 
deﬁ ned as high risk in ASTEC/EN.5 do have a signiﬁ cantly 
increased risk of disease-speciﬁ c recurrence-free survival 
compared with those classiﬁ ed as intermediate risk 
(77 events intermediate risk, 50 events high risk). 5-year 
disease-speciﬁ c recurrence-free survival for women at 
intermediate risk was 88·8% compared with 73·7% for 
high risk (absolute diﬀ erence at 5 years 15·1% 
[8·1–22·0%]). Exploratory interaction analyses of the eﬀ ect 
of external beam radiotherapy in groups deﬁ ned as 
intermediate or high risk, and in those women who had 
lymphadenectomy or no lymphadenectomy as part of 
primary surgery, are shown in ﬁ gure 4. There is no 
evidence that the eﬀ ect of external beam radiotherapy is 
diﬀ erent in subgroups of women deﬁ ned as inter-
mediate risk and high risk (test for interaction for overall 
survival p=0·83, for disease-speciﬁ c survival p=0·45). 
There is no quality evidence that the eﬀ ect of external 
beam radiotherapy is diﬀ erent in women who have had 
lymphadenectomy as part of primary surgery (test for 
interaction for overall survival=0·79, for disease-speciﬁ c 
survival p=0·22).
A Cochrane systematic review and meta-analysis 
published in 2007 identiﬁ ed three published trials 
(Aalders et al,2 GOG99,4 and PORTEC15) and one 
unpublished trial (Soderini and Sardi,3 with 123 women). 
No further trials have been identiﬁ ed. The main aim of 
updating the published review (ﬁ gure 5) was to assess the 
eﬀ ect of radiotherapy in intermediate-risk and high-risk 
early-stage disease. The Aalders trial2 was excluded 
because it was undertaken between 1968 and 1974, before 
the introduction of FIGO staging. The Soderini trial was 
Risk group
Intermediate risk 44/358 40/335 3·01 20·25
High risk 22/89 27/113 0·86 11·99
Lymphadenectomy vs no lymphadenectomy
No lymphadenectomy 48/313 51/326 1·88 24·08
Lymphadenectomy 19/139 17/127 –0·23 8·95
Risk group: interaction test, p=0·83
Lymphadenectomy vs no lymphadenectomy p=0·79
A  Overall survival (Number of events/number of women entered) Hazard ratio (ﬁxed)
Risk group
Intermediate risk 27/358 20/335 3·89 11·40
High risk 17/89 22/113 0·12 9·55
Lymphadenectomy vs no lymphadenectomy
No lymphadenectomy 33/313 28/326 4·25 14·96
Lymphadenectomy 12/139 14/127 –1·89 6·46
Risk group: interaction test, p=0·45
Lymphadenectomy vs no lymphadenectomy p=0·22
B  Disease speciﬁc survival (Number of events/number of women entered)  Hazard ratio (ﬁxed)
 
0 0·5
Favours EBRT Favours observation
1·0 1·5 2·0
EBRT Observation (O–E) Variance
EBRT Observation (O–E) Variance
Favours EBRT Favours observation
Figure 4: Eﬀ ect of external beam radiotherapy on subgroups deﬁ ned as at high and intermediate risk of recurrence and on women who had 
lymphadenectomy or no lymphadenectomy as part of initial surgery
EBRT=external beam radiotherapy. O–E=observed minus expected. Outer bars=99% CI. Inner bars=95% CI. 
See Online for webﬁ gure
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excluded because it was published in abstract form only 
with no deﬁ nitive time-to-event data. The updated 
meta-analysis of the eﬀ ect of external beam radiotherapy 
on overall survival, including ASTEC/EN.5 results, gives 
a hazard ratio of 1·04 (95% CI 0·84–1·29; p=0·38). The 
pooled results eﬀ ectively rule out an absolute beneﬁ t of 
more than a 3% increase in overall survival from adjuvant 
pelvic radiotherapy. 
Discussion
The ASTEC/EN.5 trial has shown no evidence of a beneﬁ t 
for external beam radiotherapy for early endometrial 
cancer at intermediate or high risk of recurrence, in 
terms of overall, disease-speciﬁ c, and disease-speciﬁ c 
recurrence-free survival. Combining these ﬁ ndings with 
data from other trials, we can exclude even a very small 
beneﬁ t of radiotherapy on overall survival. Adjuvant 
external beam radiotherapy did result in a small reduction 
in isolated local recurrence, but this analysis only 
included women who had local recurrence alone, and 
ignores 65% of women who had local and distant 
recurrence at the same time, or distant recurrence alone. 
The small reduction in isolated local recurrence does not 
translate into an eﬀ ect on overall or recurrence-free 
Intermediate risk
PORTEC 57 354 48 360  714 1·22
GOG 14 128 14 132  260 1·04
ASTEC+EN.5 44 358 40 335  693 1·16
Subtotal (95% CI) 115 840 102 827  1667 0·58 1·16 (0·90–1·51)
Heterogeneity: p=0·91; test for overall eﬀect: p=0·25    5-year rate of (EBRT–observation) = –2%, 95% CI = –6% to 1%
High risk
GOG 16 62 22 70  132 0·73
ASTEC+EN.5 22 89 27 113  202 1·07
Subtotal (95% CI) 38 151 49 183  334 0·88 (0·59–1·29)
Heterogeneity: p=0·33; test for overall eﬀect: p=0·51    5-year rate of (EBRT–observation) = 3%, 95% CI = –6% to 10%
Overall
PORTEC 57 354 48 360  714 1·22
GOG 30 190 36 202  392 0·86
ASTEC+EN.5 67 452 68 453  905 1·05
Subtotal (95% CI) 154 996 152 1015  2011 1·04 (0·84–1·29)
Heterogeneity: p=0·47; test for overall eﬀect: p=0·70    5-year rate of (EBRT–observation) = –1%, 95% CI = –4% to 2·4%
 EBRT   Observation HR (95% CI) N HR   
 Events Total Events Total  
 EBRT   Observation HR (95% CI) N HR   
 Events Total Events Total  
Intermediate risk
PORTEC 23 354 18 360  714 1·22
GOG 7 128 3 132  260 1·04
ASTEC+EN.5 27 358 20 335  693 1·16
Subtotal (95% CI) 57 840 41 827  1667 1·46 (0·99–2·17)
Heterogeneity: p=0·66; test for overall eﬀect: p=0·06    5-year rate of (EBRT–observation) = –2%, 95% CI = –6% to <1%
High risk
GOG 8 62 14 70  132 0·60
ASTEC+EN.5 17 89 22 113  202 1·01
Subtotal (95% CI) 25 151 36 183  334 0·81 (0·50–1·30)
Heterogeneity: p=0·29; test for overall eﬀect: p=0·38    5-year rate of (EBRT–observation) = 3%, 95% CI = –5% to 9%
Overall
PORTEC 23 354 18 360  714 1·32
GOG 15 190 17 202  392 0·93
ASTEC+EN.5 45 452 42 453  905 1·13
Subtotal (95% CI) 83 996 77 1015  2011 1·11 (0·83–1·50)
Heterogeneity: p=0·71; test for overall eﬀect: p=0·48    5-year rate of (EBRT–observation) = –1%, 95% CI = –4% to 1%
0·1 0·2
Favours EBRT Favours observation
1 2 50·5 10
A
B
Overall survival
Disease-speciﬁc survival
Favours EBRT Favours observation
Figure 5: Meta-analysis
EBRT=external beam radiotherapy. HR=hazard ratio.
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survival. Additionally, the isolated local recurrence rate 
without external beam radiotherapy (and with 
brachytherapy) is small (6·1%). With clear evidence from 
ASTEC/EN.5 that adjuvant external beam radiotherapy is 
associated with more acute and long-term toxicity than 
observation with or without brachytherapy, adjuvant 
radiotherapy after surgery to achieve isolated local control 
is not justiﬁ ed as the treatment of choice.
We are aware that there was no central pathology review 
of specimens in ASTEC. However, all pathologists in 
participating centres were given guidance to ensure that 
there was consistency across centres in the determination 
of high-risk pathology. All pathology reports were 
reviewed centrally to ensure that the histological 
description matched the diagnosis. PORTEC1 and 
GOG99 also relied on local pathology data for analyses.
The ﬁ rst trial of external beam radiotherapy in early 
endometrial cancer included all stage I women.1 
Subsequent trials selected women with intermediate-risk 
or high-risk features who were thought more likely to 
beneﬁ t from adjuvant radiotherapy. All women in the 
GOG99 trial had surgical staging, and women with 
positive lymph nodes were excluded. 30% of women in 
PORTEC1 were IB grade 2, a low-risk group considered 
ineligible for ASTEC/EN.5. Neither PORTEC1 nor GOG99 
included women with papillary serous or clear cell 
histology because they were deemed to be at high risk of 
recurrence. Although there is no standard deﬁ nition of 
intermediate-risk or high-risk endometrial cancer, a 
consensus has emerged that women with papillary serous 
or clear cell endometrial cancer, and women with all other 
histological subtypes who are stage IC with high-grade 
tumours, are at high risk of recurrence. Despite the 
negative trials, this subgroup had been thought to beneﬁ t 
from external beam radiotherapy; however, this theory is 
not supported by data from ASTEC/EN.5, with over 
200 women randomised in this high-risk category.
The number of women in ASTEC/EN.5 who had 
lymphadenectomy as part of primary surgery was small. 
Therefore, drawing ﬁ rm conclusions about any possible 
interaction of lymphadenectomy and postoperative 
adjuvant external radiotherapy is diﬃ  cult.
Brachytherapy was not allowed in either PORTEC1 or 
in GOG99. When the ASTEC and EN.5 trials were 
designed, there was a known risk of centres oﬀ ering 
brachytherapy to women assigned to the observation 
group, which could have created a bias in the trial. A 
consensus could not be reached between all collaborating 
centres as to the use of such treatment, and a third patient 
randomisation to brachytherapy versus no brachytherapy 
was felt to be impracticable. Therefore centres were asked 
to state their brachytherapy policy for all trial participants. 
Compliance with stated policy was around 80% and, 
importantly, brachytherapy was given to similar 
proportions of women in the two randomised groups.
Despite randomising higher-risk group women, the 
isolated loco-regional recurrence rate in ASTEC/EN.5 
(5-year cumulative incidence 6·1% observation vs 
3·2% external beam radiotherapy) is similar or lower 
than that seen in other trials recruiting lower-risk women 
(GOG99: 4-year cumulative incidence 7% vs 2%. 
PORTEC1: 5-year actuarial incidence 13·7% vs 4·2%). The 
ASTEC/EN.5 ﬁ ndings suggest that brachytherapy on its 
own might be an eﬀ ective strategy for local control 
(although not based on a randomised comparison).
The updated meta-analysis including ASTEC/EN.5 
results shows no beneﬁ t of external beam radiotherapy 
on overall survival in early-stage endometrial cancer. 
Previous meta-analyses have attempted to use pooled 
data to investigate the eﬀ ect of radiotherapy on diﬀ erent 
subgroups in trials whose entry criteria included 
intermediate-risk and high-risk women. Using published 
data, we could not undertake detailed subgroup analyses 
on the eﬀ ect of treatment by subtype and risk category; 
this could only be done in a meta-analysis with individual 
patient data. Using stated deﬁ nitions of risk from the 
individual trials, there is no evidence of beneﬁ t with 
external beam radiotherapy even within high-risk women. 
A meta-analysis of individual patient data might be able 
to reﬁ ne the risk group classiﬁ cation, but if the main 
interest is in the high-risk group including stage IC 
grade 3 tumours, numbers of women would be small 
(not more than 70 women in GOG99 and 202 women in 
ASTEC/EN.5), and how much a meta-analysis of 
individual patient data would add to the evidence base 
presented in the current paper is questionable.
ASTEC/EN.5 and the other relevant randomised trials 
show that external beam radiotherapy clearly has a local 
biological eﬀ ect, with a small reduction in isolated local 
recurrence, but the observation group of ASTEC/EN.5 
also shows that the use of brachytherapy could reduce 
the isolated recurrence rate at 5 years to 6·1%. The local 
eﬀ ect of external beam radiotherapy is therefore only 
modest. Considering ASTEC/EN.5 and the other 
relevant trials together, clearly any local eﬀ ect does not 
translate into a beneﬁ t in terms of reducing distant 
recurrence or death from local or distant disease or a 
beneﬁ t in terms of improved disease-speciﬁ c recurrence-
free, disease-speciﬁ c, or overall survival. One 
interpretation of the ASTEC/EN.5 data is that the 
addition of external beam radiotherapy is not necessary 
and that it is possible to achieve this low level of local 
recurrence with brachytherapy alone. Brachytherapy is a 
more convenient treatment than external beam 
radiotherapy and might be associated with less toxicity. 
Randomised data from the PORTEC2 trial, which 
directly compares brachytherapy with external beam 
radiotherapy, will provide further information. External 
beam radiotherapy does not seem to have a distant eﬀ ect 
and it might be necessary to use systemic treatments in 
very high-risk women to prevent distant metastases and 
death from endometrial cancer. In conclusion, adjuvant 
external beam radiotherapy cannot be recommended as 
part of routine treatment to improve survival for women 
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with early endometrial cancer at intermediate or high 
risk of recurrence, and brachytherapy might be preferred 
for local control.
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